You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 28, 2025

CLINICAL TRIALS PROFILE FOR IMAGABALIN

✉ Email this page to a colleague

« Back to Dashboard

Clinical Trials for Imagabalin

Subscribe to access the full database, or Get Started Free
Trial ID	Title	Status	Sponsor	Phase	Summary
NCT00542685 ↗	A 10-Week Study Evaluating the Efficacy And Safety of PD 0332334 for the Treatment of Generalized Anxiety Disorder	Completed	Pfizer	Phase 3	This study will evaluate the efficacy and safety of PD 0332334 for the treatment of generalized anxiety disorder.
NCT00658008 ↗	A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 in Patients With Generalized Anxiety Disorder (1)	Terminated	Pfizer	Phase 3	This is a 10-week trial that evaluates the efficacy and safety of PD 0332334 in subjects, ages from 18 to 65, with generalized anxiety disorder.
NCT00658372 ↗	A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 in Patients With Generalized Anxiety Disorder (2)	Terminated	Pfizer	Phase 3	This is a 10-week trial that evaluates the efficacy and safety of PD 0332334 in subjects, ages 18 to 65, with generalized anxiety disorder.
NCT00658762 ↗	A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 for the Treatment of Generalized Anxiety Disorder (3)	Terminated	Pfizer	Phase 3	This is a 10-week trial that evaluates the efficacy and safety of PD 0332334 in subjects ages 18 and older with generalized anxiety disorder.
NCT00721422 ↗	A Single Dose Study Investigating the Elimination as Well as the Tolerability of PD 0332334 in Healthy Subjects as Compared to Patients With Impaired Kidney Function.	Terminated	Pfizer	Phase 1	1. To investigate the effect of kidney function on the elimination of a single dose of PD 0332334 from the body. 2. To investigate the safety and tolerability of a single dose of PD 0332334 in patients with impaired kidney function.
NCT00730145 ↗	A Single Dose Study Investigating The Elimination Of PD-0332334 In Patients Receiving Regular Hemodialysis	Completed	Pfizer	Phase 1	1. Quantify how much PD-0332334 is removed from the blood with hemodialysis 2. Investigate the pharmacokinetics of a single dose of PD-0332334 in subjects receiving regular hemodialysis treatments. 3. Investigate the safety and tolerability of a single dose of PD-0332334 in subjects receiving hemodialysis.
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Summary

Clinical Trial Conditions for Imagabalin

Condition Name

Chart
Table

Condition Name
Intervention	Trials
Generalized Anxiety Disorder	7
Pharmacokinetics	2
Generalized Anxiety Disease	1
Renal Dialysis	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH
Intervention	Trials
Anxiety Disorders	7
Disease	5
Renal Insufficiency	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for Imagabalin

Trials by Country

Map
Table

Trials by Country
Location	Trials
United States	83
Hungary	3
Russian Federation	2
Korea, Republic of	1
Singapore	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State
Location	Trials
Florida	6
California	5
Connecticut	4
Texas	4
Pennsylvania	4
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for Imagabalin

Clinical Trial Phase

Chart
Table

Clinical Trial Phase
Clinical Trial Phase	Trials
Phase 3	4
Phase 2	1
Phase 1	5
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status
Clinical Trial Phase	Trials
Terminated	6
Completed	3
Withdrawn	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Imagabalin

Sponsor Name

Chart
Table

Sponsor Name
Sponsor	Trials
Pfizer	10
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type
Sponsor	Trials
Industry	10
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.